The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

The "Diabetes Therapeutics and Diagnostics" has been added to ResearchAndMarkets.com's offering. The global diabetes therapeutics and diagnostics market is poised for significant growth, anticipated ...

According to the latest Mordor Intelligence report, the insulin delivery devices market size is estimated at USD 33.79 billion in 2026, and is ...

An innovative insulin implant could redefine the future of diabetes management. Here's how this breakthrough diabetes treatment works, its benefits, risks, and what it means for people living with ...

Insulin Delivery Devices Market: 7.82% CAGR to 2031 Driven by Digital Insulin Pens and Pumps Transforming Diabetes Care, Says a 2026 Mordor Intelligence Report ...

The industry is projected to reach $67.39b by end-period. The global diabetes devices market is projected to grow at a ...

Insulin is a generic prescription drug approved for blood sugar management in certain animals, including dogs. Learn how to ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

According to MarketsandMarkets™, the Preparative and Process Chromatography Market is projected to grow from about USD 14.32 billion in 2026 to USD 21.50 billion by 2031, at a CAGR of 8.2%. Browse 300 ...

Sequel Med Tech and (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration.

Last week, Valerie Alcalde and her furry companion, Bowie, came for a visit to Santa Fe. Alcalde was in Santa Fe to meet with her clients that carry her brand ...

Insulet Corporation (NASDAQ: PODD) stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter earnings and 2026 guidance. Fourth-quarter adjusted earnings ...